Mymetics publishes data from groundbreaking HIV vaccine study
Epalinges, Switzerland, 15 February 2011
Mymetics Corporation, a pioneer in the development of vaccines preventing mucosal transmission of human infectious diseases, announced today that a paper describing detailed results of a successful preclinical trial on its innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine was recently published in the leading scientific journal Immunity.
|Media Name||Media Type||Description||Download|
|110214 Mymetics press release Immunity publication Final||Download|